Hepatitis B seroprevalence among children aged 0.6–14 years in Jiangsu, China, in 2023–2025
14 affiliations
- 1Department of Obstetrics and Gynecology and China Hospital Reform and Development Research Institute of Nanjing University, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China
- 2Department of Obstetrics and Gynecology, Zhenjiang Fourth People’s Hospital, Zhenjiang, Jiangsu, China
- 3Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China
- 4Department of Obstetrics and Gynecology, Wujin Hospital Affiliated with Jiangsu University, Changzhou, Jiangsu, China
- 5Department of Obstetrics and Gynecology, The Wujin Clinical College of Xuzhou Medical University, Changzhou, Jiangsu, China
- 6Department of Clinical Laboratory, Affiliated Changzhou Children’s Hospital of Nantong University, Changzhou, Jiangsu, China
- 7Department of Laboratory Medicine, Yixing Second People’s Hospital, Yixing, Jiangsu, China
- 8Department of Clinical Laboratory, The First People’s Hospital of Changzhou, Changzhou, Jiangsu, China
- 9Department of Laboratory Medicine, Affiliated Maternity and Child Health Care Hospital of Nantong University, Nantong, Jiangsu, China
- 10Department of Clinical Laboratory, Huai’an Second People’s Hospital and the Affiliated Huai’an Hospital of Xuzhou Medical University, Huai’an, Jiangsu, China
- 11Department of Clinical Laboratory, People’s Hospital of Xuyi County, Xuyi, Jiangsu, China
- 12Medical Statistics and Analysis Center, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China
- 13Department of Hepatology, Nanjing Medical University Affiliated Taizhou People’s Hospital (Jiangsu Taizhou People’s Hospital), Taizhou, Jiangsu, China
- 14Department of Infectious Diseases, Drum Tower Hospital, Nanjing University Medical School, Nanjing, China
Abstract
China has implemented universal hepatitis B vaccination in all neonates since 2002 and has enhanced prophylaxis against mother-to-child transmission of hepatitis B virus (HBV) by providing charge-free hepatitis B immunoglobulin in infants of HBV-infected mothers since 2011 and by recommending routine antiviral prophylaxis in HBV-infected mothers with high viral loads since 2020. We aimed to survey the seroprevalence of hepatitis B surface antigen (HBsAg) in children born from 2010 to 2024 in Jiangsu Province, based on convenience sampling in children who visited hospitals. We tested hepatitis B markers in 20,317 children aged 7.9 ± 4.1 years, with 11477 boys and 8840 girls, from 8 cities across Jiangsu during February 2023 to December 2025. Of them, 14 (0.069%, 95% CI: 0.038–0.116) were HBsAg positive. The positive rates of HBsAg in 0.5–<3, 3–<6, 6–<9, 9–<12, and 12–<15 years groups were 0% (0/2520), 0% (0/3858), 0.024% (1/4243), 0.136% (6/4401), and 0.132% (7/5295), respectively (P = .01489). The overall positive rate of antibody against HBsAg was 68.11% (12046/17686), with a decreasing trend over the ages (from 96.17% in 0.5–<3 year children to 48.41% in 12–<15 year children). In HBsAg-negative children, the positive rate of antibody against hepatitis B core antigen was 7.68% (1383/18007), increasing from 4.23% in 0.5–<3 year children to 7.84% in 12–<15 year children (Z = 5.0398, P < .0001). The present study showed that HBsAg prevalence among children in Jiangsu has substantially declined since the implementation of enhanced prevention of HBV perinatal infection.
Related
- Seroprevalence of measles-specific IgM and IgG antibodies among children (0–12 years) with measles-like symptoms: a hospital-based cross-sectional study in Northeast Nigeria
- Seroprevalence and awareness of hepatitis C infection among informal workers at Kejetia Market, Ghana: A cross-sectional study
- Seroprevalence of Hepatitis B Virus Infection and Associated Factors Among Blood Donors at a District Hospital in Ghana: A 2-Year Retrospective Study
- Hepatitis B vaccination coverage and factors associated with higher uptake among children aged 5–35 months in eight selected sub-Saharan African countries: a multilevel ordinal logistic regression analysis
- Seroprevalence of hepatitis B and hepatitis C and its trends in India: a systematic review and meta-analysis
BibTeX
@article{lin2026hepatitis,
title = {{Hepatitis B seroprevalence among children aged 0.6–14 years in Jiangsu, China, in 2023–2025}},
author = {Nacheng Lin and Chenyu Xu and Chang Liu and Jie Tang and Meng Gu and Guiping Zhou and Wei Zhou and Weifeng Shi and Haibo Li and Yue Jin and Jun Xie and Taishun Li and Junhao Chen and Jianchun Xian and Yi-Hua Zhou},
journal = {Human Vaccines \& Immunotherapeutics},
year = {2026},
month = nov,
doi = {10.1080/21645515.2026.2752471},
url = {https://doi.org/10.1080/21645515.2026.2752471},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Hepatitis B seroprevalence among children aged 0.6–14 years in Jiangsu, China, in 2023–2025
AU - Nacheng Lin
AU - Chenyu Xu
AU - Chang Liu
AU - Jie Tang
AU - Meng Gu
AU - Guiping Zhou
AU - Wei Zhou
AU - Weifeng Shi
AU - Haibo Li
AU - Yue Jin
AU - Jun Xie
AU - Taishun Li
AU - Junhao Chen
AU - Jianchun Xian
AU - Yi-Hua Zhou
PY - 2026
DA - 2026/11/03
JO - Human Vaccines & Immunotherapeutics
DO - 10.1080/21645515.2026.2752471
UR - https://doi.org/10.1080/21645515.2026.2752471
AB - China has implemented universal hepatitis B vaccination in all neonates since 2002 and has enhanced prophylaxis against mother-to-child transmission of hepatitis B virus (HBV) by providing charge-free hepatitis B immunoglobulin in infants of HBV-infected mothers since 2011 and by recommending routine antiviral prophylaxis in HBV-infected mothers with high viral loads since 2020. We aimed to survey the seroprevalence of hepatitis B surface antigen (HBsAg) in children born from 2010 to 2024 in Jiangsu Province, based on convenience sampling in children who visited hospitals. We tested hepatitis B markers in 20,317 children aged 7.9 ± 4.1 years, with 11477 boys and 8840 girls, from 8 cities across Jiangsu during February 2023 to December 2025. Of them, 14 (0.069%, 95% CI: 0.038–0.116) were HBsAg positive. The positive rates of HBsAg in 0.5–<3, 3–<6, 6–<9, 9–<12, and 12–<15 years groups were 0% (0/2520), 0% (0/3858), 0.024% (1/4243), 0.136% (6/4401), and 0.132% (7/5295), respectively (P = .01489). The overall positive rate of antibody against HBsAg was 68.11% (12046/17686), with a decreasing trend over the ages (from 96.17% in 0.5–<3 year children to 48.41% in 12–<15 year children). In HBsAg-negative children, the positive rate of antibody against hepatitis B core antigen was 7.68% (1383/18007), increasing from 4.23% in 0.5–<3 year children to 7.84% in 12–<15 year children (Z = 5.0398, P < .0001). The present study showed that HBsAg prevalence among children in Jiangsu has substantially declined since the implementation of enhanced prevention of HBV perinatal infection.
SN - 2164-5515
SN - 2164-554X
ER -